Topneuter (filgrastim biosimilar) / Xiamen Amoytop Biotech - LARVOL DELTA

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors (clinicaltrials.gov) - P2 | N=132 | Recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Chemotherapy-Induced Neutropenia • Hematological Disorders • Neutropenia • Oncology • Pediatrics • Solid Tumor

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors (clinicaltrials.gov) - P2 | N=132 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

New P2 trial • Chemotherapy-Induced Neutropenia • Hematological Disorders • Neutropenia • Pediatrics • Solid Tumor

Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study. (PubMed, BMC Cancer) - P3 | "This study demonstrated that telpegfilgrastim 2 mg or 33 μg/kg was non-inferior to rhG-CSF (Topneuter®) and PEG-rhG-CSF (Xinruibai®) for the management of CIN in patients with NSCLC. In particular, a 2 mg fixed dose of telpegfilgrastim presents a more convenient administration option."

Clinical • Journal • P3 data • Chemotherapy-Induced Neutropenia • Febrile Neutropenia • Hematological Disorders • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor